Home / Business News (page 3)

Business News

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

PARIS & MONTRÉAL–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced that they have entered into an agreement for Ipsen to acquire Clementia Pharmaceuticals, including its key late-stage clinical asset palovarotene, an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of …

Read More »

AbbVie and Voyager Collaborate to Develop Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies

CAMBRIDGE, Mass., and NORTH CHICAGO, Ill., Feb. 22, 2019 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, and AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced an exclusive, global strategic collaboration and option agreement to …

Read More »

Merck to Acquire Immune Design for $300 Million

KENILWORTH, N.J. & SEATTLE & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Immune Design (NASDAQ:IMDZ), today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Immune Design for $5.85 per share in …

Read More »

Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen

WALTHAM, Mass.–(BUSINESS WIRE)–Morphic Therapeutic (Morphic), a biotechnology company developing oral integrin therapies, announced today that it has entered into a research and development collaboration with Janssen Biotech, Inc. (Janssen) to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson & Johnson Innovation …

Read More »

Takeda, Microsoft and EURORDIS Release Report with Action Plan to Help Rare Disease Community Shorten the Diagnostic Odyssey

NEW YORK and BRUSSELS, Feb. 20, 2019 /PRNewswire/ — The Global Commission to End the Diagnostic Odyssey for Children (“the Global Commission”), co-chaired by Takeda, Microsoft and EURORDIS-Rare Diseases Europe, an alliance of more than 800 rare disease patient organisations, today announced its actionable recommendations in a report to address …

Read More »

Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials

NEW ORLEANS & NEW YORK–(BUSINESS WIRE)–Ochsner Health System, Louisiana’s largest non-profit academic healthcare system, and Pfizer Inc (NYSE:PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials. Through this partnership, Pfizer and Ochsner — through its innovation lab, innovationOchsner (iO), in partnership with Ochsner Research …

Read More »

Gamida Cell and Editas Medicine Partner to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate the potential use of Editas Medicine’s CRISPR technology to edit NAM-NK cells, which are natural killer cells that have been expanded using Gamida …

Read More »

Alkermes and Clovis Oncology Enter Research Collaboration to Explore Combination Cancer Therapies

DUBLIN and BOULDER, Colo., Feb. 19, 2019 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that the companies have entered into a research collaboration to evaluate ALKS 4230, Alkermes’ investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with rucaparib, Clovis’ marketed PARP inhibitor, and …

Read More »

Bayer Acquires Full Rights to Loxo Oncology’s Vitrakvi and LOXO-195

WHIPPANY, N.J., Feb. 15, 2019 /PRNewswire/ — Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization, for Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195). Both compounds are being developed globally for the treatment of adult …

Read More »

Novartis Enters 10-Target Antibody Discovery Deal with AbCellera

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera, a technology leader in therapeutic antibody discovery from natural immune repertoires, today announced a multi-target and multi-year collaboration with Novartis. Under the agreement, AbCellera will apply its expertise in antibody discovery and its single-cell screening technology to advance programs on up to ten targets elected by …

Read More »